School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Marra Jai Aghajani in
Google Scholar
PubMed
Saint Vincent’s Clinical School, UNSW Sydney, Sydney, Australia
SydPath, Saint Vincent’s Hospital, Sydney, Australia
Search for other papers by Tao Yang in
Google Scholar
PubMed
Gene & Stem Cell Therapy Program Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia
Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
Search for other papers by Ulf Schmitz in
Google Scholar
PubMed
Search for other papers by Alexander James in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Charles Eugenio McCafferty in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
School of Medicine, University of Wollongong, New South Wales, Australia
Search for other papers by Paul de Souza in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Department of Head & Neck Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
Search for other papers by Navin Niles in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Tara L Roberts in
Google Scholar
PubMed
Introduction The incidence rate of thyroid cancer has risen rapidly over the last 4 decades ( 1 ). Differentiated thyroid cancers (DTCs), derived from thyroid follicular cells, are the most common subtype, accounting for over 90% of all newly
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Search for other papers by Daniel Macedo in
Google Scholar
PubMed
Search for other papers by Maria João Bugalho in
Google Scholar
PubMed
Introduction Thyroid cancer usually has a favorable prognosis with a reported 10-year survival for differentiated and medullary thyroid carcinoma of approximately 80–95% ( 1 ) and 68–85% ( 2 , 3 ), respectively. Distant metastases occur in a
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Marra Jai Aghajani in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Tara Laurine Roberts in
Google Scholar
PubMed
Saint Vincent’s Clinical School, UNSW Sydney, Sydney, Australia
SydPath, Saint Vincent’s Hospital, Sydney, Australia
Search for other papers by Tao Yang in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Charles Eugenio McCafferty in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Centre for Oncology Education and Research Translation (CONCERT), Liverpool, New South Wales, Australia
Search for other papers by Nicole J Caixeiro in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Paul DeSouza in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Department of Head & Neck Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
Search for other papers by Navin Niles in
Google Scholar
PubMed
). Differentiated thyroid cancers (DTC; both papillary (PTC) and follicular (FTC) histologies), derived from thyroid follicular cells, are the most common subtype, accounting for approximately 90% of all newly diagnosed cases ( 2 ). Standard of care for these
Search for other papers by Mabel E Bohórquez in
Google Scholar
PubMed
Search for other papers by Ana P Estrada in
Google Scholar
PubMed
Search for other papers by Jacob Stultz in
Google Scholar
PubMed
Search for other papers by Ruta Sahasrabudhe in
Google Scholar
PubMed
Search for other papers by John Williamson in
Google Scholar
PubMed
Search for other papers by Paul Lott in
Google Scholar
PubMed
Search for other papers by Carlos S Duque in
Google Scholar
PubMed
Search for other papers by Jorge Donado in
Google Scholar
PubMed
Search for other papers by Gilbert Mateus in
Google Scholar
PubMed
Search for other papers by Fernando Bolaños in
Google Scholar
PubMed
Search for other papers by Alejandro Vélez in
Google Scholar
PubMed
Search for other papers by Magdalena Echeverry in
Google Scholar
PubMed
Genome Center and Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, California, USA
Fundación de Genética y Genómica, Medellín, Colombia
Search for other papers by Luis G Carvajal-Carmona in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) is becoming epidemic, growing in incidence both nationally and internationally ( 1 ). Nonmedullary thyroid cancer (NMTC) makes up over 95% of all cases, making it the most common endocrine malignancy ( 2
2nd Department of Internal Medicine, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Srobarova, Prague, Czech Republic
Search for other papers by T Grimmichova in
Google Scholar
PubMed
Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Videnska, Prague, Czech Republic
Search for other papers by M Haluzik in
Google Scholar
PubMed
Search for other papers by K Vondra in
Google Scholar
PubMed
Search for other papers by P Matucha in
Google Scholar
PubMed
Search for other papers by M Hill in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) is a relatively rare cancer, with an incidence from 1 to 5.3% of all malignancies, but it represents the most common malignancy originating from the endocrine organs. The most common TCs are differentiated
Search for other papers by Yanling Cai in
Google Scholar
PubMed
Search for other papers by Yan Yang in
Google Scholar
PubMed
Search for other papers by Xiao Pang in
Google Scholar
PubMed
Search for other papers by Suping Li in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) is the most common endocrine tumor, and its global incidence is increasing annually; however, the global incidence among females is 10.1 per 100,000, which is three times higher than the incidence among males
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Kim Magaly Pabst in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
Search for other papers by Robert Seifert in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Nader Hirmas in
Google Scholar
PubMed
Search for other papers by Martina Broecker-Preuss in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Manuel Weber in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Wolfgang Peter Fendler in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Timo Bartel in
Google Scholar
PubMed
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Ken Herrmann in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Rainer Görges in
Google Scholar
PubMed
over a period of >10 years. Conclusion U-hsTg measurement in patients with differentiated thyroid cancer within 24 months after completing radioiodine therapy showed higher predictive power than s-Tg measurement for RFS for a time period >10
Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Search for other papers by Tian Zhou in
Google Scholar
PubMed
Department of Surgery, Second People's Hospital of Guizhou Province, Guiyang, Guizhou, China
Search for other papers by Dai-wei Zhao in
Google Scholar
PubMed
Search for other papers by Ning Ma in
Google Scholar
PubMed
Search for other papers by Xue-ying Zhu in
Google Scholar
PubMed
Search for other papers by Xing-hong Chen in
Google Scholar
PubMed
Search for other papers by Xue Luo in
Google Scholar
PubMed
Search for other papers by Song Chen in
Google Scholar
PubMed
Search for other papers by Qing-jun Gao in
Google Scholar
PubMed
Introduction The incidence of thyroid cancer (THCA) ranks first among head and neck cancers ( 1 ). Thyroid cancer can be divided into four histological types: papillary thyroid carcinoma (PTC), follicular carcinoma, anaplastic carcinoma, and
Search for other papers by Norra Kwong in
Google Scholar
PubMed
Search for other papers by Ellen Marqusee in
Google Scholar
PubMed
Division of Endocrinology, Endocrine Division, Hypertension and Diabetes, Thyroid Section, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue Boston, Massachusetts 02115, USA
Search for other papers by Michael S Gordon in
Google Scholar
PubMed
Search for other papers by P Reed Larsen in
Google Scholar
PubMed
Division of Endocrinology, Endocrine Division, Hypertension and Diabetes, Thyroid Section, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue Boston, Massachusetts 02115, USA
Search for other papers by Jeffrey R Garber in
Google Scholar
PubMed
Search for other papers by Matthew I Kim in
Google Scholar
PubMed
Search for other papers by Erik K Alexander in
Google Scholar
PubMed
Introduction Well-differentiated thyroid cancer is common, easily identified, and often curable. While the incidence of thyroid cancer has nearly tripled in the past three decades, mortality rates have remained stable (1, 2, 3) . This underscores
Search for other papers by Teresa Kraus in
Google Scholar
PubMed
Search for other papers by Natalia Shengelia-de Lange in
Google Scholar
PubMed
Search for other papers by Holger Einspieler in
Google Scholar
PubMed
Search for other papers by Marcus Hacker in
Google Scholar
PubMed
Search for other papers by Alexander Haug in
Google Scholar
PubMed
Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed
Search for other papers by Georgios Karanikas in
Google Scholar
PubMed
this article). There was no statistically significant difference between the TNM staging in patients from Vienna and Tbilisi. The distribution of histotype showed 345 patients with papillary thyroid cancer (PTC) (93%) and 25 patients with follicular